Home -> Law Blog Directory -> Personal Injury Law Blogs -> The Personal Injury Lawyer Directory
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: The Personal Injury Lawyer DirectoryMakers of Vytorin Withheld Findings
The Senate's Finance Committee and the House's Energy and Commerce Committee allege that the makers of the cholesterol drug, Vytorin, withheld negative findings to boost sales. Drug makers Merck & Co. and Schering-Plough Corp. are accused of suppressing data that shows Vytorin is only as effective as another generic drug called Zocor, made by Merck. The findings were partially released in January due to congressional pressure.
Vytorin combines Zocor and Schering-Plough's Zetia, and was heavily advertised as a new and improved cholesterol fighting drug. This cooperative endeavor brought the companies $5.1 billion in sales in 2007.
Not only does Vytorin cost much more than Zocor, but Sen. Chuck Grassley of Iowa said in a letter that delaying the results affected medical decisions, as well as put financial strain on patients and the government. Hundreds of millions of dollars have been spent by the government since the study ended nearly two years ago. Cardiologists are recommending that doctors go back to older tried-and-true cholesterol fighting drugs.
Two Versions of Why
The government alleges that the two drug companies withheld their poor findings in order to pump up their profits, even though they realized Vytorin was not as powerful as they claimed. Sen. Grassley's letter also cites emails to Schering Plough executives from cardiologist Dr. John Kastelein. Kastelein stated that the suppression of the data was beginning to seem like it was done "for no other reason (than) political reasons."
A spokeswoman for Merck stated that executives did not find out about the findings until after January, and that interpreting the data took longer than expected. Schering-Plough's spokeswoman claims the company "did not deliberately delay" the findings to boost sales.
Stocks of both companies fell sharply after this story was reported on Monday, and has "cast a shadow" over the futures of both companies, though Merck is expected to fare better than Schering-Plough.
If you, or a loved one, have been taking Vytorin in the belief that it is better than the generic version, Zocor, you may have a pharmaceutical claim. Please contact a personal injury lawyer in your area to discuss your situation.
Full post as published by The Personal Injury Lawyer Directory on April 01, 2008 (boomark / email).
Vytorin
alleged risk of heart attack and liver damage.
Merck, Schering
Settle Vytorin Zetia Class Action
Vytorin Marketing
alleged false claims in marketing campaign.

Drug makers take Vytorin ads off the air
Vytorin: High Priced Dud Accused of False Advertising
Vytorin: Yet Another Consumer Complaint
Vytorin Makers in Marketing Mess







